Skip to main content
OpenTrials
Completed

NCT Number: NCT01228383

Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

Study design:

Single-blind (subject and observer-blinded), active-controlled, randomized [6:2:1:2:1; CL184 + purified vero cell rabies vaccine (PVRV) vs. human rabies immune globulin (HRIG) + PVRV vs. placebo + PVRV vs. CL184 + human diploid cell vaccine (HDCV) vs. placebo + HDCV], mono-center study

Study objectives:

Primary: To evaluate the safety of CL184 in combination with PVRV in healthy adult subjects.

Secondary: To evaluate the safety of HRIG or placebo in combination with PVRV and to evaluate the safety of CL184 or placebo in combination with HDCV in healthy adult subjects. To evaluate the rabies virus neutralizing activity (RVNA) after administration of CL184 or placebo in combination with PVRV, of HRIG in combination with PVRV, and of CL184 or placebo in combination with HDCV in healthy adult subjects. To evaluate the pharmacokinetics of the monoclonal antibodies (mAbs).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rabies Infections Mononegavirales Infections RNA Virus Infections Rhabdoviridae Infections Virus Diseases

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Lotus House, Vasanth Nagar

Bangalore, Karnataka, 560 052, India

About this study

This study was designed to explore and obtain further safety and RVNA data on CL184 in comparison to HRIG and placebo as part of a classical post-exposure prophylaxis (PEP) regimen. This regimen will be applied as simulated PEP regimen to healthy subjects (i.e. in a pre-exposure setting) in this study. A comparison with placebo combined with each rabies vaccine was included to differentiate between the contribution of immune globulin and vaccine and to investigate potential interactions between immune globulin and vaccine. RVNA provided by CL184 or HRIG, as well as vaccination response will be checked regularly during the study and booster doses can be applied after the study, if necessary. In addition pharmacokinetic data will be collected.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subject aged ≥18 to ≤55 years
  • Subjects free of obvious health-problems or with stable conditions or medications
  • Body mass index between ≥18 to ≤30 kg/m2
  • Abstinence from sexual intercourse or use of adequate contraception from the date of screening up to Day 90
  • Male subjects must agree that they will not donate sperm from the first check-in until Day 90
  • Subject signed written informed consent

Exclusion criteria

  • Prior history of active or passive rabies immunization
  • Clinically significant acute illness or infection including fever (≥38 °C) within 2 weeks before first dosing
  • History and/or family history of clinically significant immunodeficiency or auto-immune disease
  • Planned immunization with live vaccines during the coming 3 months after first dosing
  • Chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of investigational medicinal product

Treatment and study plan

Rabies virus-specific monoclonal antibodies

Biological

CL184 20 IU/kg intramuscularly on Day 0.

Other names: CL184

human polyclonal rabies immune globulin (HRIG)

Biological

HRIG 20 IU/kg intramuscularly on Day 0.

Other names: Imogam® Rabies-HT

Placebo

Biological

Placebo intramuscularly on Day 0.

Human diploid cell vaccine (HDCV)

Biological

Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.

Other names: Imovax®

Purified verocell rabies vaccine (PVRV)

Biological

Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.

Other names: Verorab™

Primary outcomes

  1. Number of participants with adverse events as a measure of safety

    Time frame: 90 days

    Assessed by recording unsolicited adverse events, solicited local and systemic adverse events, and pain at the injection site (assessed on a Visual Analog Scale from Day 0 to Day 3); routine safety laboratory assessed on Days -1, 1, 3, 7, 42, and 90; ECG and vital signs assessed on Days -1, 7, and 90.

Secondary outcomes

  1. Rabies virus neutralizing activity

    Time frame: 90 days

Sponsors and collaborators

Lead sponsor

Crucell Holland BV

Industry

Registry information

Official study title

A Randomized, Single-blind, Active-controlled, Mono-center Phase II Study to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Purified Vero Cell Rabies Vaccine vs. Human Rabies Immune Globulin or Placebo in Combination With Purified Vero Cell Rabies Vaccine vs. CL184 or Placebo in Combination With Human Diploid Cell Rabies Vaccine in Healthy Adult Subjects

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Oct 26, 2010
Registry last updated
Apr 10, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.